Sanofi said Friday that Main, who also joins its executive committee, will be responsible for building and maintaining the company’s position in the consumer health care market, including the expected integration of Boehringer Ingelheim business into Sanofi, which will provide a wider portfolio of brands to serve consumers globally.
The Boehringer Ingelheim deal will help Sanofi meet one of its key strategic goals, to become a leader in consumer health care and a leading, diversified global human health care company, Sanofi noted. The closing of the transaction is expected by the end of 2016.
Main has more than 30 years of marketing and general management experience in the consumer health and medical device fields. Most recently, he served as global president of Bayer Medical Care. He started his career at Stafford Miller/Block Drug (now part of GlaxoSmithKline), before joining Merrell Dow (now Sanofi) and then London Rubber Co. In 1992, he joined Roche Consumer Health and held senior roles in the United Kingdom, South Africa and Asia-Pacific. After Bayer’s acquisition of Roche Consumer Health in 2004, Main continued to hold key operational roles, including regional head for Asia-Pacific and Europe. In 2010, he was named global president of Bayer’s medical device business.
“Alan brings with him extensive experience in consumer health, and I am confident in his ability to shape the future of our Sanofi CHC business,” stated Olivier Brandicourt, chief executive officer of Sanofi. “Alan’s deep knowledge of the nonprescription medicines market and his understanding of the targeted approach towards patients and customers will allow him to contribute significantly to the overall company strategy and make him a valuable addition to Sanofi and the executive committee.”